title: Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients.
abstract: BACKGROUND
  Sirolimus (Rapamune, rapamycin, RAPA) is a potent immunosuppressive drug that has reduced the rate of acute rejection episodes by more than 40% in phase III trials when added to an immunosuppression regimen of cyclosporine (CsA) and prednisone. However, RAPA treatment tends to increase lipid levels, particularly among patients with pre-existing hyperlipidemia.
  
  
  METHODS
  To identify the metabolic pathway(s) leading to RAPA-mediated hyperlipidemia, five patients with renal transplants maintained on CsA+/-prednisone+/- azathioprine (AZA) were studied before and after 6 weeks of treatment with RAPA (off RAPA and on RAPA, respectively). Each study patient was infused with a single bolus of [2H4]-lysine to derive metabolic parameters for apoB100-containing lipoproteins by using kinetic analysis based upon quantitation of isotopic enrichment by gas chromatography-mass spectrometry.
  
  
  RESULTS
  Serial lipid measurements revealed that four patients displayed increased plasma triglyceride levels after RAPA treatment, which coincided with significantly higher plasma VLDL-apoB100 concentrations (21.7+/-12.1 mg/dl off RAPA vs. 38.7+/-14.8 mg/dl on RAPA, mean+/-SD, P<0.05). Kinetic analysis showed that the RAPA-induced increase in VLDL-apoB100 concentrations was due to a significant reduction in the fractional catabolic rate (FCR) of very low-density lipoprotein (VLDL) apoB100 (0.83+/-0.65 off RAPA vs. 0.24+/-0.10 on RAPA, mean+/-SD, P<0.05), rather than an enhanced VLDL-apoB100 synthesis. In one patient, RAPA treatment induced hypercholesterolemia but not hypertriglyceridemia. This hypercholesterolemia was due to elevated low-density lipoprotein (LDL) cholesterol levels, which coincided with a decreased FCR of LDL-apoB100. Heparin-induced lipoprotein lipase activity was significantly lower in the immunosuppressed hyperlipidemic patients than in normolipidemic controls. However, RAPA treatment did not significantly alter basal lipoprotein lipase activity in renal transplant patients in this study.
  
  
  CONCLUSIONS
  This study indicates that for renal transplant patients in whom RAPA treatment induces hyperlipidemia, this effect is the result of reduced catabolism of apoB100-containing lipoproteins.
authors.affiliation: Department of Medicine, Baylor College of Medicine, Brown-Fondren Bldg, A601, 6565 Fannin Street, Houston, TX 77030, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Hoogeveen
authors.forename: C M
authors.initials: CM
authors.lastname: Ballantyne
authors.forename: H J
authors.initials: HJ
authors.lastname: Pownall
authors.forename: A R
authors.initials: AR
authors.lastname: Opekun
authors.forename: D L
authors.initials: DL
authors.lastname: Hachey
authors.forename: J S
authors.initials: JS
authors.lastname: Jaffe
authors.forename: S
authors.initials: S
authors.lastname: Oppermann
authors.forename: B D
authors.initials: BD
authors.lastname: Kahan
authors.forename: J D
authors.initials: JD
authors.lastname: Morrisett
mesh_terms: D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000378:metabolism*; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008074:Lipoproteins / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000097:blood / Q000378:metabolism; D008954:Models, Biological; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D007166:Immunosuppressive Agents; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D020123:Sirolimus